Critical co-stimulatory pathways in the stability of Foxp3 + T reg cell homeostasis in Type I Diabetes

Autoimmunity Reviews

Volumn 11, Issue 2, 2011, Pages 104-111

  Kornete, Mara ^a,b   Piccirillo, Ciriaco A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INDUCIBLE T CELL COSTIMULATOR; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL LINEAGE; CELL MATURATION; HEMATOPOIETIC CELL; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; NEGATIVE FEEDBACK; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; THYMUS; ANIMAL; AUTOIMMUNE DISEASE; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PANCREAS ISLET; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD28; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; ISLETS OF LANGERHANS; LYMPHOCYTE ACTIVATION; MICE; PERIPHERAL TOLERANCE; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND;

EID: 84861327191     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.08.007     Document Type: Review

References (116)

1. Piccirillo C.A., d'Hennezel E., Sgouroudis E., Yurchenko E. CD4+ Foxp3+ regulatory T cells in the control of autoimmunity: in vivo veritas. Curr Opin Immunol 2008, 20:655-662.
2. Cheng M.H., Shum A.K., Anderson M.S. What's new in the Aire?. Trends Immunol 2007, 28:321-327.
3. Hogquist K.A., Baldwin T.A., Jameson S.C. Central tolerance: learning self-control in the thymus. Nat Rev Immunol 2005, 5:772-782.
4. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL- 2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
5. Asano M., Toda M., Sakaguchi N., Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996, 184:387-396.
6. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
7. Suri-Payer E., Amar A.Z., Thornton A.M., Shevach E.M. CD4+ CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998, 160:1212-1218.
8. Sakaguchi S., Regulatory T. Cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
9. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011, 10:744-755.
10. Langier S., Sade K., Kivity S. Regulatory T cells: the suppressor arm of the immune system. Autoimmun Rev 2010, 10:112-115.
11. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
12. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
13. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
14. d'Hennezel E., Ben-Shoshan M., Ochs H.D., Torgerson T.R., Russell L.J., Lejtenyi C., et al. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N Engl J Med 2009, 361:1710-1713.
15. Chang X., Zheng P., Liu Y. FoxP3: a genetic link between immunodeficiency and autoimmune diseases. Autoimmun Rev 2006, 5:399-402.
16. Rudensky A.Y., Regulatory T. Cells and Foxp3. Immunol Rev 2011, 241:260-268.
17. Alonso N., Soldevila B., Sanmartí A., Pujol-Borrell R., Martínez-Cáceres E. Regulatory T cells in diabetes and gastritis. Autoimmun Rev 2009, 8:659-662.
18. Lin Y.-T., Wang C.-T., Gershwin M.E., Chiang B.-L. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011, 10:482-489.
19. Bach J.F., Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001, 19:131-161.
20. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 1999, 5:601-604.
21. Piccirillo C.A., Tritt M., Sgouroudis E., Albanese A., Pyzik M., Hay V. Control of Type 1 autoimmune diabetes by naturally occurring CD4+ CD25+ regulatory T lymphocytes in neonatal NOD mice. Ann N Y Acad Sci 2005, 1051:72-87.
22. Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005, 23:447-485.
23. Bach J.F., Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. J Immunol 2008, 28:131-161.
24. Bluestone J., Tang Q., Sedwick C. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol 2008, 28:677-684.
25. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
26. Tritt M., Sgouroudis E., d'Hennezel E., Albanese A., Piccirillo C.A. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008, 57:113-123.
27. Sgouroudis E., Albanese A., Piccirillo C.A. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J Immunol 2008, 181:6283-6292.
28. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
29. Ueda H., Howson J.M., Esposito L., Heward J., Snook, Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
30. Maier L.M., Hafler D.A. Autoimmunity risk alleles in costimulation pathways. Immunol Rev 2009, 229:322-336.
31. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989, 7:445-480.
32. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
33. Ise W., Kohyama M., Nutsch K.M., Lee H.M., Suri A., Unanue E.R., et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol. 2010, 11:129-135.
34. Gough S.C.L., Walker L.S.K., Sansom D.M. CTLA4 gene polymorphism and autoimmunity. Immunol Rev 2005, 204:102-115.
35. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
36. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258.
37. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
38. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126.
39. Martin-Orozco N., Li Y., Wang Y., Liu S., Hwu P., Liu Y.-J., et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res 2010, 70:9581-9590.
40. Rajasalu T., Brosi H., Schuster C., Spyrantis A., Boehm B.O., Chen L., et al. Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic β-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 2010, 59:1966-1973.
41. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006, 203:883-895.
42. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
43. Bour-Jordan H., Bluestone J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009, 229:41-66.
44. Bour-Jordan H., Esensten J.H., Martinez-Llordella M., Penaranda C., Stumpf M., Bluestone J.A. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 2011, 241:180-205.
45. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19:225-252.
46. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol 2003, 171:3348-3352.
47. Fraser J., Irving B., Crabtree G., Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991, 251:313-316.
48. Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., et al. Pillars article: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995; 3:87-98. J Immunol 2010, 185:3788-3799.
49. Appleman L.J., Berezovskaya A., Grass I., Boussiotis V.A. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2000, 164:144-151.
50. Lohr J., Knoechel B., Kahn E.C., Abbas A.K. Role of B7 in T cell tolerance. J Immunol 2004, 173:5028-5035.
51. Tai X., Cowan M., Feigenbaum L., Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005, 6:152-162.
52. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
53. Liu Z., Geboes K., Hellings P., Maerten P., Heremans H., Vandenberghe P., et al. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J Immunol 2001, 167:1830-1838.
54. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., et al. Immunologic self-tolerance maintained by Cd25+ Cd4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte associated antigen 4. J Exp Med 2000, 192:303-310.
55. Crispín J.C., Tsokos G.C. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 2009, 8:190-195.
56. Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
57. D'Cruz L.M., Klein L. Development and function of agonist-induced CD25+ Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005, 6:1152-1159.
58. van Berkel M.E.A.T., Oosterwegel M.A. CD28 and ICOS: similar or separate costimulators of T cells?. Immunol Lett 2006, 105:115-122.
59. Yoshinaga S.K., Whoriskey J.S., Khare S.D., Sarmiento U., Guo J., Horan T., et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999, 402:827-832.
60. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
61. Mages H.W., Hutloff A., Heuck C., Büchner K., Himmelbauer H., Oliveri F., et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000, 30:1040-1047.
62. Nurieva R.I., Liu X., Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009, 229:88-100.
63. Zhang J., Dong C., Nurieva R., Martin-Orozco N. Co-stimulation regulation of immune tolerance and autoimmunity. Immune Regulation and Immunotherapy in Autoimmune Disease 2007, 121-138. Springer, US.
64. Dong C., Nurieva R., Prasad D. Immune regulation by novel costimulatory molecules. Immunol Res 2003, 28:39-48.
65. Sperling A.I., Bluestone J.A. ICOS costimulation: it's not just for TH2 cells anymore. Nat Immunol 2001, 2:573-574.
66. Dong C., Nurieva R.I. Regulation of immune and autoimmune responses by ICOS. J Autoimmun 2003, 21:255-260.
67. Prevot N., Briet C., Lassmann H., Tardivel I., Roy E., Morin J., et al. Abrogation of ICOS/ICOS ligand costimulation in NOD mice results in autoimmune deviation toward the neuromuscular system. Eur J Immunol 2010, 40:2267-2276.
68. Herman A.E., Freeman G.J., Mathis D., Benoist C. CD4+ CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004, 199:1479-1489.
69. Bauquet A.T., Jin H., Paterson A.M., Mitsdoerffer M., Ho I.C., Sharpe A.H., et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 2009, 10:167-175.
70. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, et al. The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells. Sci Transl Med 2010;2:55ra78.
71. Bonhagen K., Liesenfeld O., Stadecker M.J., Hutloff A., Erb K., Coyle A.J., et al. ICOS+ Th cells produce distinct cytokines in different mucosal immune responses. Eur J Immunol 2003, 33:392-401.
72. McAdam A.J., Greenwald R.J., Levin M.A., Chernova T., Malenkovich N., Ling V., et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001, 409:102-105.
73. Bossaller L., Burger J., Draeger R., Grimbacher B., Knoth R., Plebani A., et al. ICOS deficiency is associated with a severe reduction of CXCR5+ CD4 germinal center Th cells. J Immunol 2006, 177:4927-4932.
74. Dong C., Juedes A.E., Temann U.-A., Shresta S., Allison J.P., Ruddle N.H., et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001, 409:97-101.
75. Coyle A.J., Lehar S., Lloyd C., Tian J., Delaney T., Manning S., et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000, 13:95-105.
76. Simpson T.R., Quezada S.A., Allison J.P. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 2010, 22:326-332.
77. Riley J.L., Blair P.J., Musser J.T., Abe R., Tezuka K., Tsuji T., et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J Immunol 2001, 166:4943-4948.
78. Sporici R.A., Beswick R.L., von Allmen C., Rumbley C.A., Hayden-Ledbetter M., Ledbetter J.A., et al. ICOS ligand costimulation is required for T-cell encephalitogenicity. Clin Immunol 2001, 100:277-288.
79. Burmeister Y., Lischke T., Dahler A.C., Mages H.W., Lam K.-P., Coyle A.J., et al. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 2008, 180:3613.
80. Ito T., Hanabuchi S., Wang Y.-H., Park W.R., Arima K., Bover L., et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
81. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010, 207:1871-1878.
82. Löhning M., Hutloff A., Kallinich T., Mages H.W., Bonhagen K., Radbruch A., et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003, 197:181-193.
83. Ansari M.J.I., Fiorina P., Dada S., Guleria I., Ueno T., Yuan X., et al. Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol 2008, 126:140-147.
84. Warnatz K., Bossaller L., Salzer U., Skrabl-Baumgartner A., Schwinger W., van der Burg M., et al. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006, 107:3045-3052.
85. Blank C., Brown I., Marks R., Nishimura H., Honjo T., Gajewski T.F. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol 2003, 171:4574-4581.
86. Nishimura H., Honjo T., Minato N. Facilitation of beta selection and modification of positive selection in the thymus of Pd-1-deficient mice. J Exp Med 2000, 191:891-898.
87. Zucchelli S., Holler P., Yamagata T., Roy M., Benoist C., Mathis D. Defective central tolerance induction in NOD Mice: genomics and genetics. Immunity 2005, 22:385-396.
88. Keir M.E., Freeman G.J., Sharpe A.H. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 2007, 179:5064-5070.
89. Dinesh R.K., Hahn B.H., Singh R.P. PD-1, gender, and autoimmunity. Autoimmun Rev 2010, 9:583-587.
90. Nielsen C., Hansen D., Husby S., Jacobsen B.B., Lillevang S.T. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003, 62:492-497.
91. Ni R., Ihara K., Miyako K., Kuromaru R., Inuo M., Kohno H., et al. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum Genet 2007, 121:223-232.
92. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka K.V., Mäurer M., et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005, 58:50-57.
93. Lin S.-C., Yen J.-H., Tsai J.-J., Tsai W.-C., Ou T.-T., Liu H.-W., et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004, 50:770-775.
94. Kong E.K.-P., Prokunina-Olsson L., Wong W.H.-S., Lau C.-S., Chan T.-M., Alarcón-Riquelme M., et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005, 52:1058-1062.
95. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
96. Ansari M.J.I., Salama A.D., Chitnis T., Smith R.N., Yagita H., Akiba H., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003, 198:63-69.
97. Wang J., Yoshida T., Nakaki F., Hiai H., Okazaki T., Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 2005, 102:11823-11828.
98. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009, 10:1185-1192.
99. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009, 206:3015-3029.
100. Totsuka T., Kanai T., Makita S., Fujii R., Nemoto Y., Oshima S., et al. Regulation of murine chronic colitis by CD4+ CD25- programmed death-1+ T cells. Eur J Immunol 2005, 35:1773-1785.
101. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010, 236:219-242.
102. Fiorina P. β-cells step up in controlling the autoimmune response. Diabetes 2010, 59:1861-1864.
103. Guerder S., Picarella D.E., Linsley P.S., Flavell R.A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1994, 91:5138-5142.
104. Havari E., Lennon-Dumenil A.M., Klein L., Neely D., Taylor J.A., McInerney M.F., et al. Expression of the B7.1 costimulatory molecule on pancreatic β cells abrogates the requirement for CD4 T cells in the development of type 1 diabetes. J Immunol 2004, 173:787-796.
105. Zeng M., Guinet E., Nouri-Shirazi M. B7-1 and B7-2 differentially control peripheral homeostasis of CD4+ CD25+ Foxp3+ regulatory T cells. Transpl Immunol 2009, 20:171-179.
106. Yadav D., Fine C., Azuma M., Sarvetnick N. B7-1 mediated costimulation regulates pancreatic autoimmunity. Mol Immunol 2007, 44:2616-2624.
107. Yadav D., Sarvetnick N. B7-2 regulates survival, phenotype, and function of APCs. J Immunol 2007, 178:6236-6241.
108. Bar-On L., Birnberg T., Kim K.-w., Jung S. Dendritic cell-restricted CD80/86 deficiency results in peripheral regulatory T-cell reduction but is not associated with lymphocyte hyperactivation. Eur J Immunol 2010, 41:291-298.
109. Sgouroudis E., Kornete M., Piccirillo C.A. IL-2 production by dendritic cells promotes Foxp3+ regulatory T-cell expansion in autoimmune-resistant NOD congenic mice. Autoimmunity 2011, 5:406-414.
110. Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003, 33:2706-2716.
111. Haller M.J., Atkinson M.A., Schatz D.A. Efforts to prevent and halt autoimmune beta cell destruction. Endocrinol Metab Clin North Am 2010, 39:527-539.
112. Rottman J.B., Smith T., Tonra J.R., Ganley K., Bloom T., Silva R., et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001, 2:605-611.
113. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009, 106:1903-1908.
114. Zhou L., Chong M.M.W., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
115. McClymont S.A., Putnam A.L., Lee M.R., Esensten J.H., Liu W., Hulme M.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011, 186:3918-3926.
116. Bailey-Bucktrout S.L., Bluestone J.A. Regulatory T cells: stability revisited. Trends Immunol. 2011, 32:301-306.